Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial-Reference-Cited by-同舟云学术

Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

Published:2021-01 Issue: Volume:143 Page:55-63
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Boilève Alice,Hilmi Marc,Gougis Paul,Cohen Romain,Rousseau Benoît,Blanc Jean-Frédéric,Ben Abdelghani Meher,Castanié Hélène,Dahan Laëtitia,Tougeron David,Metges Jean-Philippe,Tournigand Christophe,Garcia-Larnicol Marie-Line,Vernerey Dewi,Turpin Anthony^ORCID,Neuzillet Cindy^ORCID

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference28 articles.

1. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma;Bridgewater;J Hepatol,2014

2. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Valle;Ann Oncol,2016

3. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010

4. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: hoosier Oncology group GI06-101;Chiorean;Oncol,2012

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer;Current Treatment Options in Oncology;2024-07-27

2. “On/off”-switchable crosslinked PTX-nanoformulation with improved precise delivery for NSCLC brain metastases and restrained adverse reaction over nab-PTX;Biomaterials;2024-06

3. Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date;OncoTargets and Therapy;2024-05

4. Unresectable biliary tract cancer: Current and future systemic therapy;European Journal of Cancer;2024-05

5. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review);International Journal of Oncology;2023-10-27